Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 1.00 |
| ▸ | MAFG | O15525 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.87 |
| ▸ | HTT | P42858 | 3/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CFTR | P13569 | 5/20 | 0.46 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440736 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085609 | 1.00 | SMN1; SMN2 (1.00) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085530 | 0.96 | SMN1; SMN2 (0.92) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085439 | 0.94 | SMN1; SMN2 (0.88) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085453 | 0.93 | SMN1; SMN2 (1.00) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085434 | 0.93 | SMN1; SMN2 (0.87) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085466 | 0.92 | SMN1; SMN2 (0.85) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085431 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085413 | 0.91 | SMN1; SMN2 (0.86) | SMN1; SMN2POLBMAFGHPGDNFE2L2 | |
| SCHEMBL16085432 | 0.91 | SMN1; SMN2 (0.83) | SMN1; SMN2POLBMAFGHPGDNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12458630-B2 | Combination therapy for cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-04 | — | — | US | claimed |
| CN-120053506-A | Application of crocodile flower extract in preparation of medicines for preventing and treating hepatotoxicity caused by nonylphenol based on MAPK-Nrf2 pathway | 华南农业大学 | 2025-05-30 | — | — | CN | claimed |
| CN-119909154-A | Application of phycocyanin in preparation of drugs for reducing expression level of cell apoptosis marker | 安徽医科大学第一附属医院 | 2025-05-02 | — | — | CN | claimed |
| CN-119868583-A | Nanometer reactor for jointly blocking autophagy and megacytosis, and preparation method and application thereof | 江苏省人民医院（南京医科大学第一附属医院） | 2025-04-25 | — | — | CN | claimed |
| CN-119280229-A | Application of NFE2L2 inhibitor in preparation of medicine for inhibiting endometriosis focus growth | 中国福利会国际和平妇幼保健院 | 2025-01-10 | — | — | CN | claimed |
| CN-117180272-A | Application of Nrf2 inhibitor ML385 in induction of iron death of lung cancer cells | 南通大学 | 2023-12-08 | — | — | CN | claimed |
| EP-4203943-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | ArtemiFlow GmbH (DE) | 2023-07-05 | — | — | EP | claimed |
| US-20230149346-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | Artemiflow GmbH (DE) | 2023-05-18 | — | — | US | claimed |
| US-20230130791-A1 | A Combined Inhibition of EGFR and NRF2 in The Treatment of Malignant Glioma | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-04-27 | — | — | US | claimed |
| US-20230068698-A1 | COMBINATION THERAPY FOR CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-02 | — | — | US | claimed |
| EP-4117788-A1 | COMBINED INHIBITION OF EGFR AND NRF2 IN THE TREATMENT OF MALIGNANT GLIOMA | UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2023-01-18 | — | — | EP | claimed |
| US-20220347125-A1 | ANTITUMOR AGENT AND COMPOUNDING AGENT | KEIO UNIVERSITY (JP) | 2022-11-03 | — | — | US | claimed |
| WO-2022175402-A1 | QUINUCLIDINE-3-ONE DERIVATIVES | APREA THERAPEUTICS AB (SE) | 2022-08-25 | — | — | WO | claimed |
| CN-114588153-A | Application of small molecule inhibitor ML385 in inhibition of tumor cell PD-L1 | 南通大学 | 2022-06-07 | — | — | CN | claimed |
| EP-3973991-A1 | ANTI-TUMOR AGENT AND COMPOUNDING AGENT | Keio University (JP) | 2022-03-30 | — | — | EP | claimed |
| US-20220071970-A1 | QUINUCLIDINE-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT | APREA THERAPEUTICS AB (SE) | 2022-03-10 | — | — | US | claimed |
| CN-114126652-A | Antitumor agent and compounding agent | 学校法人庆应义塾 | 2022-03-01 | — | — | CN | claimed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20220071970-A1 | QUINUCLIDINE-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT | APREA THERAPEUTICS AB (SE) | 2022-03-10 | — | — | US | disclosed |
| CN-114126652-A | Antitumor agent and compounding agent | 学校法人庆应义塾 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220071970-A1 | QUINUCLIDINE-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT | NQO2, MKI67, NQO1 | SMN1; SMN2 4653/4885POLB 340/4885MAFG 2095/4885 |
| US-20230149346-A1 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | PRDX4, CA4, TOP1 | SMN1; SMN2 3924/4885POLB 1441/4885MAFG 2988/4885 |
| US-20220347125-A1 | ANTITUMOR AGENT AND COMPOUNDING AGENT | GSTA1, GSTP1, GSTA2 | SMN1; SMN2 4738/4885POLB 1474/4885MAFG 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.